Kornimate/medical-research-clean huggingface dataset:
effect of tolvaptan on mid- to long-term prognosis of heart failure patients

Conditions: Heart Failure

Summary: one tolvaptan 15 mg tablet or placebo tablet will be orally administered once daily in the morning for up to 14 days to heart failure patients with volume overload that does not show adequate response to other diuretics such as loop diuretics in order to investigate the effect of tolvaptan on the mid- to long-term prognosis of the target population. the efficacy of tolvaptan during the treatment period will also be investigated.


Eligibility criteria:
inclusion criteria: * patients from whom informed consent has been properly obtained in writing prior to start of the trial * patients who have been clinically diagnosed with heart failure * patients with any of the following conditions or symptoms: lower limb edema, dyspnea, jugular venous distension, hepatomegaly, pulmonary rales, third heart sound, or pulmonary congestion * patients who have been receiving loop diuretics, thiazide diuretics, or anti-aldosterone diuretics * male or female patients of age 20 to 85 years inclusive (at time of informed consent) * patients who, together with their partner(s), are able to use an appropriate method of contraception until 3 months after final trial drug administration * patients who are able to be hospitalized at the trial site for at least 7 days from the start of trial drug administration exclusion criteria: * patients with a history of hypersensitivity to any ingredient of the drug or to tolvaptan analogues (e.g., mozavaptan hydrochloride) * patients with anuria * patients who cannot sense thirst or who have difficulty with fluid intake * patients with hypernatremia (serum sodium concentration \> institutional upper limit of normal) 5) female patients who are pregnant, possibly pregnant, or nursing * patients judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial due to any of the following conditions or symptoms: * hyponatremia (serum sodium concentration \< 125 meq/l) * serious coronary artery disease or cerebrovascular disease * hyperkalemia * severe renal disorder * poorly controlled diabetes mellitus * severe hepatic disease * impaired urinary excretion due to urinary stenosis, calculus, or tumor * cardiac valve disease with significant heart valve stenosis * malignant tumor of unfavorable prognosis * patients with suspected hypovolemia * patients with an implanted circulatory support device * patients in whom acute cardiac infarction occurred within 30 days prior to the screening examination * patients who participated in any other clinical trial or postmarketing clinical trial within 30 days prior to the date of informed consent for the present trial * patients who received tolvaptan within 26 weeks prior to the date of informed consent * patients who are otherwise judged by the investigator or sub-investigator to be inappropriate for inclusion in the trial

Keywords: heart failure volume overload tolvaptan loop diuretics
smartphone use and neck flexion angle

Conditions: Neck Disorder

Summary: excessive smartphone use can disrupt your sleep, which can have a serious impact on your overall mental health. it can impact your memory, affect your ability to think clearly, and reduce your cognitive and learning skills. encouraging self-absorption.

persistent failed attempts to use cell phone less often. preoccupation with smartphone use. turns to cell phone when experiencing unwanted feelings such as anxiety or depression. excessive use characterized by loss of sense of time. nomophobia-an abbreviation of "no-mobile-phone-phobia"-is also called "cell phone addiction." symptoms include: experiencing anxiety or panic over losing your phone. obsessively checking for missed calls, emails, and texts.

Eligibility criteria:
inclusion criteria: * volunteers using smartphone less or more than 4 hours per day exclusion criteria: * low back pain surgeries affecting upper limps

Keywords: smartphone neck flexion
pharmacist provided intervention (education and medication review) in osteoarthritis

Conditions: Osteoarthritis; Pain

Summary: the purpose of this study is to initiate pharmacist intervention (educational and medication review) among osteoarthritis patients visiting community pharmacies.

community pharmacists are one of the most accessible health care professionals for patient care in chronic diseases including osteoarthritis and can provide patient education, conduct medication review, and collaborate with the multidisciplinary pain management team, to improve treatment outcomes and quality of life. studies have reported that pharmacist-provided intervention was beneficial as it increased patients' knowledge of osteoarthritis, reduced the rates of adverse events associated with analgesics, and improved self-perceived health and function. so this study aims to provide intervention through community pharmacists. potential patients will be identified from community pharmacies and consent will be obtained from patients before enrolling them in the study. the study will be a cluster-randomized trial. thus pharmacies will be randomized, either to control or treatment group. patients in the treatment group will receive the pharmacist-initiated intervention while in the control group will receive usual care. the intervention will be an education on osteoarthritis, its management, and self-care activities followed by a medication review. pharmacists assess patients' knowledge of medication indication, identify adverse effects or drug-related problems, and counsel patients on proper medication use. education intervention will be provided through face-to-face communication at the time of enrollment and a leaflet will be provided. the patient will receive a phone call and will be able to view the video in the succeeding weeks to enforce the intervention. outcome measures will be assessed at baseline, three months, and six months from enrolment in both treatment and control groups.

Eligibility criteria:
inclusion criteria: * patient aged 18 years and above with the complaint of osteoarthritis * patient willing to participate in the study * patient with chronic pain (persisting for more than three months) exclusion criteria: * patient unable to provide the consent due to severe mental health, cognitive impairment or learning difficulties * patient with a terminal illness * patient having sufficient knowledge on osteoarthritis, its management and self-care activities as assessed from the questionnaire (respond correctly to 80% of the question or above)
a study of osi-7904l as treatment in patients with head and neck cancer who have failed first-line therapy

Conditions: Locally Recurrent or Metastatic Cancer of the Head and Neck; Must Have Failed First-Line Therapy

Summary: multi-center, phase ii study to evaluate the efficacy and safety of osi-7904lin head and neck cancer in patients who have failed first-line therapy


Eligibility criteria:
inclusion criteria: histologically or cytologically confirmed metastatic or locally recurrent scchn that is incurable with surgery or radiation therapy ecog performance status 0-2 no more tha 1 prior chemotharapy regimen for metastatic or locally recurrent disease adequate bone marrow, hepatic and renal function. at least one target lesion greater than or equal to 20 mm. exclusion criteria: symptomatic brain metasteses which are not stable, are not adequately controlled, are potenially life threatening or required radiation in the last 28 days pregnant or lactating women. concurrent anticancer therapy or other investigational drugs patients with active or uncontrolled infections or other serious illnesses or medical conditions.
continued early intervention for recent-onset schizophrenia

Conditions: Schizophrenia

Summary: the purpose of this study was to determine whether outreach integrated treatment of first episode schizophrenia was more effecive than standard outpatient treatment.

early intervention for schizophrenia has spawned considerable enthusiasm among clinicians without solid research evidence to suport its benefits and costs. the present study is a random-controlled study of integrated biomedical and psychosocial treatment on a population of recent-onset cases. comparison(s): 50 consecutive referrals with schizophrenic disorders of less than two years duration were allocated randomly to a comprehensive model of integrated treatment or standard care for two years. main outcome measures was psychopathology, psychosocial functioning and hospital admissions.

Eligibility criteria:
inclusion criteria: * first-episode schizophrenia exclusion criteria: * acute psychosis

Keywords: schizophrenia psychosocial treatment outcome
evaluation of the invest in play program - a new parent intervention for children with problem behavior

Conditions: Problem Behavior; Attention Deficit and Disruptive Behavior Disorders

Summary: the goal of this clinical trial is to test if the invest in play (iip) parent program can reduce problem behaviors in children and improve parenting practices in families with children who show challenging behaviors. the main questions it aims to answer is: • does the iip program reduce children's problem behaviors? researchers will compare families in the iip program to families in a control group to see if the program leads to better outcomes for children and parents. participants will be randomly assigned to either the iip program group or the control group and complete surveys before and after the program to see if iip is reducing children's problem behaviors.


Eligibility criteria:
inclusion criteria: * parents of children between 6-12 years of age referred to out-patient clinics for treatment of behavioural problems. * children scoring above a pre-defined mean cut off score (over the 90 percentile) on the eyberg child behavior inventory (ecbi; eyberg \& ross, 1978) based on norwegian norms (reedtz et al., 2008), as reported by parents. exclusion criteria: - severe developmental delay (in children or parents), autism spectrum disorder, inability to understand norwegian, or other reasons why the parent(s) are not expected to benefit from group therapy.

Keywords: parent intervention parent practices emotion regulation parent-child relationship parental attributions
analysis of retinal vessel pulsations with electrocardiographic gating

Conditions: Vessels; Anomaly

Summary: analysis of retinal vessel analyzer (rva) recordings of retinal vessel pulsations, and putting them in context of intraocular pressure (iop) pulsations by means of electrocardiographic (ecg) gating, in order to determine the lead source for pulsations of retinal veins.

rationale / objective is to construct the retinal vessels wall pulsation cycle using an electrocardiographic gating, and to analyse it in comparison with an analogue intraocular pressure (iop) cycle. based on the amplitude and on the phase shift of pulsations of retinal vessel wall, the goal is to identify a lead source of the retinal venous pulsations (iop pulsations, or alternative sources, e.g. cerebrospinal fluid pulsations). subjects will be recruited from the environment of the master thesis medical students, colleagues and friends and the informed consent will be handed to them personally. exclusion criteria will be addressed. one random eye per subject will be selected. on the study day, first the mydriasis drops - phenylephrine + tropicamide - will be applied, then ecg electrodes attached; 20 minutes after the mydriasis drops, the first set of measurements will be performed: rva recording with ecg gating, and pascal dynamic contour tonometry (dct) recording with ecg gating. ten minutes after this measurements, 100% oxygen 5 liters/min through nasal cannula will be applied for 2 minutes and then the same measurements repeated. approximate time needed for the whole run - around 60 minutes per subject, including (dis)mounting the ecg electrodes and the mydriasis time.

Eligibility criteria:
inclusion criteria: - exclusion criteria: known ophthalmological disease, in particular vascular disease.
efficacy of quantum npwt with simultaneous irrigation on reduction of wound volume in stage iii/iv pressure ulcers.

Conditions: Pressure Ulcers

Summary: negative-pressure wound therapy (npwt) is an important adjunct for management of wounds, and promotes granulation tissue and angiogenesis. despite these known means for facilitation of wound management, further research is needed to examine whether this modality is superior to other currently used options, thus defining clear indications for and benefits of npwt. this would also help establish the role of combination therapy, using npwt with simultaneous irrigation or other forms of dressings. this study aims to compare treatment efficacy of npwt, npwt plus proprietary simultaneous irrigation, and traditional hospital standard of care for treatment of grade iii \& iv pressure ulcers. primary endpoint of this study is comparison of reduction of wound volume between the three treatment arms; and secondary endpoints include bacterial load, rate of wound healing, preparation for grafting, and pain.


Eligibility criteria:
inclusion criteria: * male or female between the ages of 18 and 70 * any patient with a stage iii/iv pressure ulcer of the size large enough to indicate use of negative pressure treatment. exclusion criteria: * clinical evidence of active, gross infection. * patient or patient's guardian refuses consent.

Keywords: negative pressure wound therapy irrigation therapy pressure ulcers sacral ulcers
pilot study of loop diuretics among individuals receiving hemodialysis

Conditions: Chronic Kidney Disease Requiring Chronic Dialysis

Summary: individuals with kidney failure receiving maintenance hemodialysis (hd) have high mortality rates, driven largely by cardiovascular causes. volume-related factors are critical, modifiable contributors to cardiovascular complications. reversing volume overload has been shown to improve blood pressure and cardiac remodeling. use of loop diuretics may represent a pragmatic, low-cost, and low-burden strategy to improve outcomes in people receiving hd. lack of data on optimal furosemide dosing, safety, and acceptability are barriers to expanded use. this study investigates whether oral furosemide is safe and effective at increasing urine volume in hd patients.


Eligibility criteria:
inclusion criteria: * patient self-report of at least 1 cup urine/24-hours * age ≥18 years * receipt of thrice weekly in-center hd at a participating clinic (unc-associated carolina dialysis- carrboro, siler city, pittsboro, sanford, and lee county) * ≥60 days receiving in-center hd * willingness to take study medication and undergo study testing * ability to provide informed consent exclusion criteria: * known allergy to loop diuretic * history of poor adherence to hd or medical regimen per nephrologist * \>1 hospitalization in prior 30-days * frequent hypotension (systolic bp \ 30% of hd treatments in prior 30-days) * cirrhosis per nephrologist * hearing disorder per nephrologist * serum potassium \<3.5 meq/l, magnesium \<1 mg/dl, or corrected calcium \<8 mg/dl in prior 30-days * taking a non-loop diuretic (e.g. spironolactone, eplerenone, ethacrynic acid, thiazides) * taking an aminoglycoside, cisplatin, methotrexate, cyclosporine, adrenocorticotropic hormone (acth), lithium, phenytoin, or oral/intravenous steroid * natural licorice consumption * prisoners, patients with significant mental illness * pregnant patients and nursing mothers

Keywords: hemodialysis dialysis end stage renal disease patient-reported outcomes symptoms diuretic furosemide lasix
influence of anesthesia methods on surgical outcomes and renal function

Conditions: Kidney Calculi

Summary: patients who underwent retrograde intrarenal surgery (rirs) were randomly allocated to general anesthesia (ga) or spinal anesthesia (sa) groups. renal function was assessed using estimated glomerular filtration rate, and relative renal function was evaluated using nuclear medicine tests. maneuverability and accessibility were evaluated after every surgery. we analyzed the influence of anesthesia methods on surgical outcomes and renal function in retrograde intrarenal surgery in a prospective, randomized controlled study.


Eligibility criteria:
inclusion criteria: * older than 20 years with renal stones greater than 10 mm exclusion criteria: * patients who have urologic anatomical abnormalities * patients with asa status ≥ grade iii, a contraindication for spinal anesthesia or rirs, or unexpected intraoperative renal injury
clinical evaluation of cats tonometer prism

Conditions: Ocular Hypertension

Summary: prospective, open-labeled, randomized, controlled, multicenter study at two clinical investigative sites in tucson, arizona. the subjects will undergo intraocular pressure measurement with the cats tonometer prism and the goldmann applanation tonometer prism (gat). of the 200 eyes, at least 10 highly astigmatic eyes (\>3 d of corneal astigmatism) each in the low, medium and high iop ranges shall have the same clinical testing and analysis of results, with the analysis kept separate from that of the main group.


Eligibility criteria:
inclusion criteria: * written informed consent (and assent when applicable)obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study. * male and female patients, at least 18 years of age exclusion criteria: * subject has undergone ocular surgery within the last 3 months * uncontrolled systemic disease that in the opinion of the investigator would put the subject's heath at risk * pregnant or nursing women * subjects with only one functional eye * those with one eye having poor or eccentric fixation * eyes displaying an oval contact image * those with corneal scarring or who have had corneal surgery including corneal laser surgery * microphthalmos * buphthalmos * contact lens wearers * severe dry eyes * lid squeezers - blepharospasm * nystagmus * keratoconus * any other corneal or conjunctival pathology or infection. * central corneal thickness greater than 0.600 mm or less than 0.500 mm (2 standard deviations about the human mean)
evaluation of the effect of telmisartan on blood pressure control of high risk patients

Conditions: Hypertension

Summary: the study is designed to evaluate the effect of treatment with micardis/micardisplus on blood pressure and its ability to reduce different indicated cardiovascular risk scores. the study will also evaluate the current antihypertensive treatment pattern in the daily practice among the patient population at increased cardiovascular risk.


Eligibility criteria:
inclusion criteria: * diagnosis of essential arterial hypertension (bp\>140/90 mm hg or bp\>130/80 mm hg for diabetic patients) * at least one additional cardiovascular risk factor and/or known single or multiple end organ damage and/or previous cardiovascular disease exclusion criteria: * hypersensitivity to the active substance or to any of the excipients in any ace inhibitor or angiotensin receptor blocker (arb) available on the local market, as prescribed in the spc * pregnancy and lactation * diseases involving biliary obstruction * severe liver impairment * severe hypertension * malignant hypertension * secondary hypertension * patients age under 18 years
long-term follow-up study for participants of kite-sponsored interventional studies treated with gene-modified cells

Conditions: Solid and Hematological Malignancies

Summary: the goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, kite-363, kite-753, kite-197, and anitocabtagene autoleucel in participants of kite-sponsored interventional studies.


Eligibility criteria:
inclusion criteria: * the individual must have received an infusion of gene-modified cells in a completed kite-sponsored parent study, has not withdrawn full consent, and has discontinued or completed the post-treatment follow-up period in the parent study, as applicable * the individual must understand and voluntarily sign an informed consent form (icf) or an informed assent form prior to any study-related assessments or procedures being conducted * in the investigator's judgment, the individual is willing and able to complete the protocol-required follow-up schedule and comply with the study requirements for participation exclusion criteria: none
ni-0401 in patients with acute renal allograft rejection

Conditions: Acute Renal Transplant Rejection

Summary: the purpose of the study is to determine the safety and tolerability of ni-0401 and whether ni-0401 can reverse bpacr.


Eligibility criteria:
main inclusion criteria: * evidence of cellular rejection in a renal biopsy according to bannff 97 criteria * rise in serum creatinine concentration by \>20% compared to baseline value main exclusion criteria: * previous therapy with anti-cd3 mab(okt3) or anti-lymphocytes polyclonal antibodies (atg, atgam) * patients with cardiac insufficiency or fluid overload * severe hla sensitization (\>50% panel reactive antibodies prior transplantation) * defined concomitant disease
evaluation of different psychiatric symptoms in patients with thyroid dysfunction

Conditions: Anxiety; Depression; Thyroid Dysfunction

Summary: 1. evaluate psychiatric symptoms in patients with thyroid dysfunction. 2. investigate effect of treatment on psychiatric symptoms after 2 months.

thyroid dysfunction is associated with psychiatric symptoms in addition to endocrinal manifestations. the study aims to evaluate the prevalence of psychiatric symptoms in patients with thyroid dysfunction and investigate the response after thyroid treatment.

Eligibility criteria:
inclusion criteria: * patients newly diagnosed as having thyroid dysfunction. exclusion criteria: * patients with other endocrinological disorders or significant medical or neurological diseases. * alcohol or substance abuse